Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update

Journal of Clinical Oncology

Volumn 37, Issue 15, 2019, Pages 1336-1351

  Bohlius, Julia ^a   Bohlke, Kari ^b   Castelli, Roberto ^c   Djulbegovic, Benjamin ^d   Lustberg, Maryam B ^e   Martino, Massimo ^f   Mountzios, Giannis ^g   Peswani, Namrata ^h   Porter, Laura ⁱ   Tanaka, Tiffany N ^j   Trifirò, Gianluca ^k   Yang, Hushan ^l   Lazo Langner, Alejandro ^m  

^a UNIVERSITY OF BERN   (Switzerland)

^b AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^c UNIVERSITY OF MILAN   (Italy)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^g HENRY DUNANT HOSPITAL   (Greece)

^h Lutheran General Hospital   (United States)

ⁱ National Patient Advocate Foundation   (United States)

^j UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^k UNIVERSITY OF MESSINA   (Italy)

^l THOMAS JEFFERSON UNIVERSITY   (United States)

^m UNIVERSITY OF WESTERN ONTARIO   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; BIOSIMILAR AGENT; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; CANCER PATIENT; COCHRANE LIBRARY; HUMAN; MALIGNANT NEOPLASM; MEDLINE; META ANALYSIS (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; BLOOD; NEOPLASM;

ANEMIA; BIOSIMILAR PHARMACEUTICALS; HEMATINICS; HUMANS; META-ANALYSIS AS TOPIC; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85066163723     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.18.02142     Document Type: Article

References (55)

1. Grant MD, Piper M, Bohlius J, et al: AHRQ Comparative Effectiveness Reviews:Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment: Comparative Effectiveness Update. Comparative Effectiveness Review No. 113 (AHRQ Publication No. 13-EHC077-EF). Rockville, MD, Agency for Healthcare Research and Quality, 2013. www.effectivehealthcare.ahrq.gov/reports/final.cfm
2. Tonia T, Mettler A, Robert N, et al: Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 12:CD003407, 2012
3. Leyland-Jones B, Semiglazov V, Pawlicki M, et al: Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol 23:5960-5972, 2005
4. Thomas G, Ali S, Hoebers FJ, et al: Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol 108:317-325, 2008
5. Untch M, von Minckwitz G, Konecny GE, et al: PREPARE trial: A randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer-outcome on prognosis. Ann Oncol 22:1999-2006, 2011
6. Leyland-Jones B, Bondarenko I, Nemsadze G, et al: A randomized, open-label, multicenter, phase III study of epoetin alfa versus best standard of care in anemic patients with metastatic breast cancer receiving standard chemotherapy. J Clin Oncol 34:1197-1207, 2016
7. U.S. Food and Drug Administration: Information on erythropoiesis-stimulating agents (ESA) epoetin alfa (marketed as Procrit, Epogen), darbepoetin alfa (marketed as Aranesp). https://www.fda.gov/Drugs/DrugSafety/ucm109375.htm
8. Rizzo JD, Lichtin AE, Woolf SH, et al: Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20:4083-4107, 2002
9. Rizzo JD, Somerfield MR, Hagerty KL, et al: Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 26:132-149, 2008
10. Rizzo JD, Brouwers M, Hurley P, et al: American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 28:4996-5010, 2010
11. U.S. Food and Drug Administration: FDA approves Retacrit as a biosimilar to Epogen/Procrit. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm607723.htm
12. Shojania KG, Sampson M, Ansari MT, et al: How quickly do systematic reviews go out of date? A survival analysis. Ann Intern Med 147:224-233, 2007
13. Aapro M, Moebus V, Nitz U, et al: Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: A meta-analysis. Ann Oncol 26:688-695, 2015
14. Bohlius J, Tonia T, Nuesch E, et al: Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: Systematic review and meta-analyses of published and unpublished data. Br J Cancer 111:33-45, 2014
15. Gafter-Gvili A, Rozen-Zvi B, Vidal L, et al: Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia - systematic review and meta-analysis of randomised controlled trials. Acta Oncol 52:18-29, 2013
16. Gao S, Ma JJ, Lu C: Venous thromboembolism risk and erythropoiesis-stimulating agents for the treatment of cancer-associated anemia: A meta-analysis. Tumour Biol 35:603-613, 2014
17. Hedenus M, Osterborg A, Tomita D, et al: Effects of erythropoiesis-stimulating agents on survival and other outcomes in patients with lymphoproliferative malignancies: A study-level meta-analysis. Leuk Lymphoma 53:2151-2158, 2012
18. Li X, Yan Z, Kong D, et al: Erythropoiesis-stimulating agents in the management of cancer patients with anemia: A meta-analysis. Chin J Cancer Res 26: 268-276, 2014
19. Marchetti C, De Felice F, Palaia I, et al: Erythropoiesis-stimulating agents in gynecological malignancies: A study-level meta-analysis. Crit Rev Oncol Hematol 99:123-128, 2016
20. Mhaskar R, Wao H, Miladinovic B, et al: The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. Cochrane Database Syst Rev 2:CD009624, 2016
21. Ohashi Y, Uemura Y, Fujisaka Y, et al: Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials. Cancer Sci 104:481-485, 2013
22. Petrelli F, Borgonovo K, Cabiddu M, et al: Addition of iron to erythropoiesis-stimulating agents in cancer patients: A meta-analysis of randomized trials. J Cancer Res Clin Oncol 138:179-187, 2012
23. Tomlinson D, Robinson PD, Oberoi S, et al: Pharmacologic interventions for fatigue in cancer and transplantation: A meta-analysis. Curr Oncol 25:e152-e167, 2018
24. Vansteenkiste J, Glaspy J, Henry D, et al: Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: Study-level and patient-level meta-analyses. Lung Cancer 76:478-485, 2012
25. Zhan P, Wang Q, Qian Q, et al: Risk of venous thromboembolism with the erythropoiesis-stimulating agents (ESAs) for the treatment of cancer-associated anemia: A meta-analysis of randomized control trials. Linchuang Zhongliuxue Zazhi 1:19, 2012
26. Toma A, Kosmider O, Chevret S, et al: Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion. Leukemia 30:897-905, 2016
27. Amato L, Addis A, Saulle R, et al: Comparative efficacy and safety in ESA biosimilars vs. originators in adults with chronic kidney disease: A systematic review and meta-analysis. J Nephrol 31:321-332, 2018
28. Hahn D, Esezobor CI, Elserafy N, et al: Short-acting erythropoiesis-stimulating agents for anaemia in predialysis patients. Cochrane Database Syst Rev 1: CD011690, 2017
29. Weir MR, Pergola PE, Agarwal R, et al: A comparison of the safety and efficacy of HX575 (epoetin alfa proposed biosimilar) with epoetin alfa in patients with end-stage renal disease. Am J Nephrol 46:364-370, 2017
30. Weigang-Köhler K, Vetter A, Thyroff-Friesinger U: HX575, recombinant human epoetin alfa, for the treatment of chemotherapy-associated symptomatic anaemia in patients with solid tumours. Onkologie 32:168-174, 2009
31. Giordano G, Mondello P, Tambaro R, et al: Biosimilar epoetin a is as effective as originator epoetin-a plus liposomal iron (Sideral®), vitamin B12 and folates in patients with refractory anemia: A retrospective real-life approach. Mol Clin Oncol 3:781-784, 2015
32. Rodriguez Garzotto A, Cortijo Casacajares S, Pernaut C, et al: Erythropoiesis-stimulating agents for the treatment of chemotherapy-induced anemia: Comparisons from real-world clinical experience. J Blood Med 5:43-48, 2014
33. Trotta F, Belleudi V, Fusco D, et al: Comparative effectiveness and safety of erythropoiesis-stimulating agents (biosimilars vs originators) in clinical practice: A population-based cohort study in Italy. BMJ Open 7:e011637, 2017
34. Ingrasciotta Y, Giorgianni F, Marcianò I, et al: Comparative effectiveness of biosimilar, reference product and other erythropoiesis-stimulating agents (ESAs) still covered by patent in chronic kidney disease and cancer patients: An Italian population-based study. PLoS One 11:e0155805, 2016
35. Cella D, Eton DT, Lai JS, et al: Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 24:547-561, 2002
36. Bohlius J, Schmidlin K, Brillant C, et al: Erythropoietin or darbepoetin for patients with cancer-meta-analysis based on individual patient data. Cochrane Database Syst Rev (3):CD007303, 2009
37. Hellström-Lindberg E, Gulbrandsen N, Lindberg G, et al: A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: Significant effects on quality of life. Br J Haematol 120:1037-1046, 2003
38. Fenaux P, Santini V, Spiriti MAA, et al: A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-a in anemic patients with low-risk MDS. Leukemia 32:2648-2658, 2018
39. Hellström-Lindberg E, Ahlgren T, Beguin Y, et al: Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: Results from a randomized phase II study and long-term follow-up of 71 patients. Blood 92:68-75, 1998
40. Aapro M, Krendyukov A, Schiestl M, et al: Epoetin biosimilars in the treatment of chemotherapy-induced anemia: 10 years’ experience gained. BioDrugs 32: 129-135, 2018 [Erratum: BioDrugs 32:137-138, 2018]
41. Goldsmith D, Dellanna F, Schiestl M, et al: Epoetin biosimilars in the treatment of renal anemia: What have we learned from a decade of European experience? Clin Drug Investig 38:481-490, 2018
42. Lyman GH, Khorana AA, Kuderer NM, et al: Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31:2189-2204, 2013
43. Bennett CL, Angelotta C, Yarnold PR, et al: Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA 296:2558-2560, 2006
44. Shepshelovich D, Rozen-Zvi B, Avni T, et al: Intravenous versus oral iron supplementation for the treatment of anemia in CKD: An updated systematic review and meta-analysis. Am J Kidney Dis 68:677-690, 2016
45. Gilligan T, Coyle N, Frankel RM, et al: Patient-clinician communication: American Society of Clinical Oncology consensus guideline. J Clin Oncol 35:3618-3632, 2017
46. US Cancer Statistics Working Group: United States cancer statistics: 1999–2012 incidence and mortality web-based report. Atlanta, GA, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute, 2015. https://gis.cdc.gov/Cancer/USCS/DataViz.html
47. Howlader N, Noone AM, Krapcho M, et al: SEER cancer statistics review, 1975-2013. http://seer.cancer.gov/csr/1975_2013/
48. Mead H, Cartwright-Smith L, Jones K, et al: Racial and Ethnic Disparities in U.S. Health Care: A Chartbook. New York, NY, The Commonwealth Fund, 2008
49. American Cancer Society: Cancer facts and figures for African Americans 2016-2018. http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-047403.pdf
50. Schnipper LE, Davidson NE, Wollins DS, et al: Updating the American Society of Clinical Oncology value framework: Revisions and reflections in response to comments received. J Clin Oncol 34:2925-2934, 2016
51. Schnipper LE, Davidson NE, Wollins DS, et al: American Society of Clinical Oncology statement: A conceptual framework to assess the value of cancer treatment options. J Clin Oncol 33:2563-2577, 2015
52. Dusetzina SB, Winn AN, Abel GA, et al: Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol 32: 306-311, 2014
53. Streeter SB, Schwartzberg L, Husain N, et al: Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions. J Oncol Pract 7:46s-51s, 2011 (3; suppl)
54. Meropol NJ, Schrag D, Smith TJ, et al: American Society of Clinical Oncology guidance statement: The cost of cancer care. J Clin Oncol 27:3868-3874, 2009
55. Ferrell BR, Temel JS, Temin S, et al: Integration of palliative care into standard oncology care: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35:96-112, 2017